Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Cortexyme Inc (QNCX) operate in?
Cortexyme Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cortexyme Inc (QNCX) current stock price?
As of the latest data, Cortexyme Inc stock price is $31.73, with a previous close of $29.36. Cortexyme Inc gained $2.37 in the last trading session, representing a 8.07% increase.
What is Cortexyme Inc (QNCX) current market capitalization?
Cortexyme Inc market cap is approximately 32.27 million.
What is Cortexyme Inc (QNCX) Earnings Per Share (EPS)?
The trailing EPS is -$210.84, and the forward EPS is -$4.68.
What is Cortexyme Inc (QNCX) EBITDA?
Cortexyme Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -75.41 million.
Does Cortexyme Inc (QNCX) pay dividends?
No. Cortexyme Inc does not pay a dividend.
When is Cortexyme Inc (QNCX) next earnings report?
Cortexyme Inc is expected to release its next earnings report on September 30, 2026.
What is Cortexyme Inc (QNCX) beta (volatility) score?
Cortexyme Inc has a beta of 1.309, suggesting it is more volatile than the market.
